Calcium channel blockers not found to increase risk of breast cancer
the ONA take:
According to findings presented at the 2014 American Heart Association Scientific in Chicago, Illinois, researchers from the Intermountain Medical Center Heart Institute in Murray, Utah, have found that women who take calcium channel blockers to treat their hypertension are not at increased risk for developing breast cancer.
Prompted by a study conducted last year at the Fred Hutchinson Cancer Research Center in Seattle, Washington, researchers conducted two studies by analyzing data from the records of more than 3,700 women ages 50 to 70 years with no history of breast cancer who had used calcium channel blockers long-term to treat their high blood pressure.
For each study, researchers compared women who had long-term use of calcium channel blockers to similar women who did not take those medications. In one study, they found a slight increase in breast cancer risk, and a 50% decreased risk in the second study.
The second study's findings were significant, but the odds of breast cancer were much lower than those observed in the study at Fred Hutchinson. As a result, the researchers recommend the continued use of calcium channel blockers to treat hypertension, thereby reducing the risk of myocardial infarction and stroke.
Women who take calcium channel blockers to treat their hypertension are not at increased risk.
Researchers analyzed the records of more than 3,700 women who had no history of breast cancer, and who had long-term use of calcium channel blocker medications to control their blood pressure. Researchers found only a minimal increase in risk in one study and a 50 percent reduced risk in a second, leading them to recommend the continued use of these important medications to help prevent heart attack and stroke.
Findings from the Intermountain Medical Center Heart Institute study will be presented at the 2014 American Heart Association Scientific in Chicago at 10:30, EST, on Wednesday, November 19.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Pediatric Hepatocellular Carcinoma: Challenges and Solutions
- Earlier and Later Adult BMI Associated With Multiple Myeloma Risk
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- VBPWPs Can Compliment Patient Management in Clinical Trials
- Communication Technology Improves Treatment Burden, Patient Perspective of Oncology Care
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|